VERONA PHARMA P/S (NASDAQ:VRNA) had its target price raised by stock analysts at SunTrust Banks from $29.00 to $34.00 in a note issued to investors on Tuesday, The Fly reports. The brokerage currently has a “buy” rating on the stock. SunTrust Banks’ target price would indicate a potential upside of 486.21% from the company’s current price.
Several other brokerages have also recently commented on VRNA. Zacks Investment Research cut VERONA PHARMA P/S from a “buy” rating to a “hold” rating in a research report on Saturday, November 16th. Wedbush raised their target price on VERONA PHARMA P/S from $58.00 to $60.00 and gave the stock an “outperform” rating in a research report on Monday. Five research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus price target of $29.44.
Shares of VERONA PHARMA P/S stock traded down $0.15 during midday trading on Tuesday, hitting $5.80. The company had a trading volume of 2,400 shares, compared to its average volume of 624,755. The business’s 50 day simple moving average is $4.93 and its two-hundred day simple moving average is $4.56. The stock has a market cap of $83.08 million, a PE ratio of -2.89 and a beta of -0.78. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.07 and a quick ratio of 4.07. VERONA PHARMA P/S has a 1-year low of $3.65 and a 1-year high of $12.89.
An institutional investor recently raised its position in VERONA PHARMA P/S stock. IHT Wealth Management LLC increased its position in VERONA PHARMA P/S (NASDAQ:VRNA) by 18.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,460 shares of the company’s stock after purchasing an additional 3,130 shares during the quarter. IHT Wealth Management LLC owned approximately 0.16% of VERONA PHARMA P/S worth $94,000 at the end of the most recent quarter. 55.89% of the stock is currently owned by institutional investors.
VERONA PHARMA P/S Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis.
See Also: Rule of 72
Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with MarketBeat.com's FREE daily email newsletter.